Product information and disease descriptionProduct description
Phase of product development
18 evidence topics · 17 sources
Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive
Launch
No evidence found.
Authorisation status in the European Union: not authorised
| Field | Quoted record |
|---|---|
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Active substance | “Inaxaplin” |
| Authorisation status | “Not authorised” |
| Medicine status in the EU | “No EU-wide authorisation listed” |
Pivotal AMPLITUDE trial: full enrollment completed in 2026
Interim analysis timing: company guidance from January 2025 to November 2026
Interim analysis endpoints: company wording from March 2022 to September 2025
Interim analysis endpoints: registered primary endpoints
Interim analysis endpoint agreed with the FDA: eGFR slope
Breakthrough Therapy designation for APOL1-mediated FSGS, June 2022
PRIME designation for AMKD, May 2022
Rare Pediatric Disease designation for APOL1-mediated FSGS
EU orphan designation EU/3/22/2697, October 2022
| Field | Quoted record |
|---|---|
| Active substance | “Inaxaplin” |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/22/2697” |
| Date of designation | “11/10/2022” |
| Sponsor | “Vertex Pharmaceuticals (Ireland) Limited” |
EU paediatric investigation plan EMEA-003368-PIP01-22, agreed October 2023
| Field | Quoted record |
|---|---|
| Active substance | “Inaxaplin” |
| Decision number | “P/0430/2023” |
| PIP number | “EMEA-003368-PIP01-22” |
| Pharmaceutical form | “Film-coated tablet” |
| Condition | “Treatment of apolipoprotein L1 (APOL1)-mediated kidney disease” |
| Route of administration | “Oral use” |
| Decision date | “27/10/2023” |
FDA orphan drug and Fast Track designations
No evidence found.
First-in-human study, June 2019 to January 2020
“The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study 1 was conducted at two sites in the United States (Madison, WI and Dallas, TX) between June 2019 and January 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote